In a commentary attributed to Bridgett Fertig, the central claim is that the same large corporations accused of contributing to cancer—by producing or enabling harmful exposures—also fund cancer research. The stated purpose of this dual role is presented as public relations and influence rather than a genuine, independent commitment to cures. According to the argument, these companies can support research publicly to create the appearance of seeking solutions while simultaneously benefiting from the continued conditions that lead to cancer in the first place.
Fertig frames the issue as a conflict of interest embedded throughout the system. The account emphasizes that corporate power is not limited to laboratory funding; it extends into the legislative process itself. In her portrayal, corporations are said to operate on both sides of major bills moving through Washington—supporting certain measures when it suits them and opposing or weakening others when regulation threatens their interests. The thrust of the critique is that corporations do not merely participate in policy debates; they allegedly influence outcomes before legislation is finalized, effectively determining what protections the public receives.
A key part of the accusation is that corporations are positioned to shape the very laws intended to regulate them. Fertig argues that because these companies have extensive leverage—through lobbying, campaign support, and other mechanisms—they help write or steer legislation that should restrict their behavior. The summary of the claim is that lawmakers and the regulatory framework do not function as a neutral check on corporate activity; instead, industry influence can make regulation more favorable to corporate interests.
The text further asserts that this dynamic reaches into the leadership and membership of Congress. Fertig’s statement suggests that corporations “own all of Congress,” meaning that policy decisions reflect corporate priorities more than public health needs. In this view, the process is not simply biased; it is fundamentally captured. As a result, the public is left with limited protection, while corporate entities continue to manage both reputational narratives and legal environments.
Underlying the critique is a broader question about trust in cancer research and the governance of public health. By claiming that corporations fund cancer research in order to “pretend to look for a cure,” Fertig implies that research funding can be used strategically to maintain credibility, secure public confidence, and distract from responsibility. The implication is not that all research is fraudulent, but that the sponsorship and policy influence surrounding it can create incentives that slow meaningful prevention, reduce accountability, or steer scientific priorities toward outcomes that are less disruptive to corporate business models.
The commentary also points to a systemic pattern: corporations are depicted as simultaneously generating harm and funding the response. This creates an environment where the same actors can benefit from both the problem and the attempt to address it. Fertig’s message is that this arrangement allows corporations to maintain power, even as cancer affects communities across the country.
Overall, the news story is less about a single event and more about an allegation concerning the structure of influence in both scientific funding and federal policy. The recurring theme is capture: that the entities blamed for contributing to cancer exposures are also deeply embedded in the mechanisms that regulate them and fund related research. Fertig’s framing emphasizes the need to question incentives, examine who benefits from research and legislation, and scrutinize whether public health efforts are being shaped to protect corporate interests.
The statement concludes with a sweeping criticism of Congress as controlled or heavily influenced by corporate ownership and influence. By portraying corporations as sitting on both sides of every bill and helping draft the legislation meant to regulate them, the commentary suggests that the public has limited recourse through the standard democratic process. In Fertig’s telling, this is why corporate funding of cancer research and corporate influence in Washington are linked: both are part of the same strategy to preserve corporate power while managing public perception.
Source: Source
Bridgett Fertig: The same corporations that poison you to give you cancer are also funding the cancer research to pretend to look for a cure. They sit on both sides of every bill drafted in Washington, they write the legislation that’s supposed to regulate them because they own all of Congress,. #breaking
— @LightOnLiberty May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
